Biologics processes continue to evolve after approval. This guide explains how ICH Q12 uses Established Conditions, PACMPs, PLCM documents, and the PQS to make post-approval CMC changes more predictable and risk-based.

Biologics quality cannot rely on release testing alone. This guide explains how to build an integrated strategy across materials, manufacturing, analytics, specifications, and continued monitoring.

Passing release specifications does not establish comparability. Learn how ICH Q5E integrates risk assessment, analytical characterization, stability, process data, and regulatory strategy.